N a s d a q : I N S Y

Size: px
Start display at page:

Download "N a s d a q : I N S Y"

Transcription

1 N a s d a q : I N S Y 0

2 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations and assumptions as of the date of this presentation, and actual results may differ materially from those in these forward-looking statements as a result of various factors, including many which are beyond Insys control. Such factors include, but are not limited to risks regarding: Insys' ability to commercialize products successfully; Insys ability to successfully manage its commercial relationships and sales infrastructure; Insys ability to obtain anticipated governmental or regulatory approvals; Insys failure to comply with post-approval regulatory and governmental requirements; the actual sales potential and opportunity of identified markets; and Insys ability to realize the expectations of its pipeline and product candidate plans and timelines. For a further description of these and other risks facing Insys, please see the risk factors described in the company's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption Risk Factors in those filings. All the information included herein is dated information concerning the company. The company disclaims and does not undertake any obligation to update or revise any forwardlooking statements or historical information contained herein. 1

3 Saeed Motahari, President & CEO - 20-year veteran of the life sciences industry - 8 years at Hoffmann-La Roche and Bristol-Myers Squibb Led various functional areas in the commercial organization - 10 year tenure at Abbott Laboratories & AbbVie Vice President of US Specialty Brands New Launches P&L responsibility for Specialty Franchises in multiple therapeutic areas - Purdue Pharma Chief Commercial Officer Led successful transformation of commercial organization 2

4 Insys Highlights - Differentiated products and novel proprietary drug platforms offer substantial room for growth - Addressing underserved population of patients with breakthrough cancer pain with our market leading Subsys sublingual spray - Poised to launch SYNDROS (dronabinol) oral solution in August Advancing deep pipeline with multiple opportunities to deliver long-term value in the business - State of the art manufacturing capabilities for pharmaceutical cannabinoids 3

5 Strategic Roadmap Mission Improve the quality of patient care by building a specialty pharmaceutical company focused on cannabinoids and novel drug delivery systems that address unmet patient needs Strategic Imperatives Strengthen the Foundation Stabilize and Strengthen Portfolio Advance Our Pipeline Resolve Government Investigations 4

6 Strategic Imperatives Strengthen the Foundation Stabilize and Strengthen Portfolio Advance Our Pipeline Resolve Government Investigations Optimize and align structure Stabilize Subsys Spray technology Federal Strengthen commercial, medical and business partnership capabilities Launch SYNDROS TM Optimize Lifecycle initiatives for both products Cannabinoid platform States Recruit, Develop & Retain Talent 5

7 Leveraging Two Drug Delivery Platforms Spray Technology Drug delivery via a fine mist: beneath the tongue (sublingual) in the nasal cavity (nasal) Targeting supportive care & other markets where spray product characteristics add value Ease of use / application Clinically beneficial faster speed of onset Pharmaceutical Cannabinoids SYNDROS to be positioned as a best-in-class pharmaceutical THC product Emerging cannabidiol (CBD) product pipeline 6

8 Subsys - Offering relief to patients with breakthrough cancer pain Onset of action as early as 5 minutes Seven doses from 100 to 1,600mcg Simple one-step administration process takes < 1 minute - Market leader despite challenges to TIRF product class - Market share stabilizing at ~35% Opportunities to stabilize and grow the product - Educating market about breakthrough cancer pain to improve treatment rate - Improve access - Improve adherence 7

9 SYNDROS Commercial Opportunity - SYNDROS (dronabinol) oral solution, CII, approved for: Anorexia associated with weight loss in patients with AIDS Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments - Current market at ~280k prescriptions 2, with potential addressable population of ~800K in CINV and ~90k in AIDS anorexia - Concentrated universe of ~4K prescribers write 50% of scripts Prescriber Overview 1 Preparing for August 2017 launch (1) 2016 IMS TRx data (2) Source Health Analytics TRx data 8

10 SYNDROS Commercial Strategy - Position as a best-in-class pharmaceutical THC product - Launch with existing sales force to concentrated universe of prescribers - Two-pronged approach 1. Convert existing Marinol market 2. Expand the market Highlight improved product profile - Hybrid distribution model specialty pharma and retail Peak SYNDROS sales potential >$200M 9

11 SUBLINGUAL SPRAYS CANNABINOIDS Deep Pipeline to Drive Long-Term Growth Drug Candidate Buprenorphine Sublingual Spray Subsys Label Expansion Disease State Moderate to severe Pain Post operative pain and pre-procedural pain Pre- Clinical Phase 3 Completed Phase 1 Phase 2 Phase 3 Submit Approval Dose Ranging Studies Completed Naloxone Nasal Spray Opioid Overdose In Development Buprenorphine / Naloxone Sublingual Spray Opioid Dependence In Development Fentanyl / Menthol Breakthrough cancer pain in patients 18 yo In Development Epinephrine Anaphylaxis Reaction In Development Syndros (i) CINV & (ii) anorexia associated with weight loss in patients with AIDS Approved Syndros Label Expansion (i) Agitation in Alzheimer s disease (ii) Anorexia In Development Cannabidiol (i) Epilepsy and other indications PK Study in refractory epilepsy completed 10

12 Cannabinoids - Growth Strategy SYNDROS TM Approved July 2016 for Nausea / Vomiting Associated with Cancer Chemotherapy and Anorexia / Weight Loss in Patients with AIDS Life Cycle Management Alzheimer's Agitation Anorexia in cancer patients Inhaled delivery Cannabidiol Pediatric Epilepsies Addiction & other indications CINV: chemotherapy induced nausea & vomiting 11

13 Cannabinoid Manufacturing Capabilities U.S.-based facility approved to produce pharmaceutical dronabinol (THC) and cannabidiol (CBD) with scale for commercial quantities Expanding manufacturing capacity to support future demand Constructed second facility to manufacture API for dronabinol oral solution and pharmaceutical CBD Capable of producing over 99% pure CBD synthetically in a controlled environment 12

14 Insys Financial Snapshot - Cash flow generated will fund future growth - $218.5 million in cash, cash equivalents & investments as of March 31, No debt Revenue ($mm) Adjusted EBITDA ($mm) $350 $330.3 $140 $128.3 $300 $120 $250 $200 $219.1 $242.3 $100 $80 $78.8 $150 $100 $99.3 $60 $40 $40.6 $39.1 $50 $15.5 $20 $ $0 -$20 -$ $

15 Insys Highlights - Differentiated products and novel proprietary drug platforms offer substantial room for growth - Addressing underserved population of patients with breakthrough cancer pain with our market leading Subsys sublingual spray - Poised to launch SYNDROS (dronabinol) oral solution in August Advancing deep pipeline with multiple opportunities to deliver long-term value in the business - State of the art manufacturing capabilities for pharmaceutical cannabinoids 14

Q3 18 Earnings Supplemental Slides

Q3 18 Earnings Supplemental Slides (Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements

More information

Investor Presentation

Investor Presentation (Nasdaq: INSY) Investor Presentation Cantor Global Healthcare Conference October 2, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking

More information

Investor Presentation

Investor Presentation (Nasdaq: INSY) Investor Presentation Janney Healthcare Conference September 18, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking

More information

DARA Reports Year-End 2012 Financial Results

DARA Reports Year-End 2012 Financial Results April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,

More information

27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009

27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009 27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»

More information

AXIM Biotechnologies Reports Year End 2017 Results

AXIM Biotechnologies Reports Year End 2017 Results March 19, 2018 AXIM Biotechnologies Reports Year End 2017 Results NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research

More information

COMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing

COMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing COMPANY PRESENTATION JULY 2018 Bob Bechard Executive Vice-President Corporate Development & Licensing Forward Looking Statements Some statements in this release may contain forward-looking information.

More information

Acorda Acquisition of Civitas Therapeutics. September 24, 2014

Acorda Acquisition of Civitas Therapeutics. September 24, 2014 Acorda Acquisition of Civitas Therapeutics September 24, 2014 Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform

More information

J.P. Morgan Healthcare Conference

J.P. Morgan Healthcare Conference J.P. Morgan Healthcare Conference Shire plc January 10, 2012 Angus Russell Chief Executive Officer Our purpose We enable people with life-altering conditions to lead better lives. THE SAFE HARBOR STATEMENT

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019

37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019 37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts,

More information

4Q and Full Year 2017 Financial Results Call February 7, 2018

4Q and Full Year 2017 Financial Results Call February 7, 2018 4Q and Full Year 2017 Financial Results Call February 7, 2018 Agenda Topic Welcome Opening Remarks 4Q 2017 Results Commercial Progress Question & Answer Speakers Amy Sullivan, SVP, Corporate Affairs Greg

More information

Investor Presentation March 2015

Investor Presentation March 2015 Investor Presentation March 2015 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the

More information

LEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017

LEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017 LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting

More information

Supernus Pharmaceuticals

Supernus Pharmaceuticals Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include

More information

34 th Annual J.P. Morgan Healthcare Conference

34 th Annual J.P. Morgan Healthcare Conference JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains

More information

Strengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018

Strengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Strengthening our global leadership in treatment of addiction Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Forward Looking Statements This presentation contains certain statements

More information

Cowen Healthcare Conference

Cowen Healthcare Conference Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT

More information

BDSI Corporate Overview

BDSI Corporate Overview BDSI Corporate Overview June 2017 1 2017 BioDelivery Sciences International Inc. All Rights Reserved. Jefferies 2017 Healthcare Conference Dr. Mark A. Sirgo President and Chief Executive Officer June 6

More information

Innovation In Ophthalmics

Innovation In Ophthalmics Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016 ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),

More information

36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018

36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018 36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section

More information

Egalet Corporate Presentation

Egalet Corporate Presentation Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking

More information

SPECIALTY MEDICAL CANNABIS COMPANY

SPECIALTY MEDICAL CANNABIS COMPANY SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward

More information

AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes

AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,

More information

Company Overview February 26, 2019

Company Overview February 26, 2019 Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,

More information

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE 37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines

SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and

More information

COMPANY PRESENTATION. Bernard Fortier, CEO

COMPANY PRESENTATION. Bernard Fortier, CEO COMPANY PRESENTATION Bernard Fortier, CEO Forward Looking Statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address

More information

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company

More information

Lauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST

Lauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST Lauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST Forward Looking Statements Certain statements contained

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.

More information

Merrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007

Merrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007 Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical

More information

Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation

Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals

More information

GW Pharmaceuticals plc. Investor Presentation August 2014

GW Pharmaceuticals plc. Investor Presentation August 2014 GW Pharmaceuticals plc Investor Presentation August 2014 Forward Looking Statements and Disclaimer This presentation contains forward-looking statements. Some of the matters discussed concerning our operations

More information

H. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011

H. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011 H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts

More information

Photocure ASA Executing the Strategy

Photocure ASA Executing the Strategy Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address

More information

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)

More information

Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results

Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,

More information

Committed to Transforming the Treatment Paradigm for Migraine Prevention

Committed to Transforming the Treatment Paradigm for Migraine Prevention June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking

More information

Sucampo Pharmaceuticals, Inc. Jefferies 2015 Healthcare Conference

Sucampo Pharmaceuticals, Inc. Jefferies 2015 Healthcare Conference Sucampo Pharmaceuticals, Inc. Jefferies 2015 Healthcare Conference June 3, 2015 Peter Greenleaf Chief Executive Officer Forward-Looking Statements This presentation contains "forward-looking statements"

More information

Presentation to AGM 9 November Deborah Rathjen CEO & Managing Director

Presentation to AGM 9 November Deborah Rathjen CEO & Managing Director Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the

More information

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER

More information

Ipsen Acquisition of Clementia Pharmaceuticals. February 25, 2019

Ipsen Acquisition of Clementia Pharmaceuticals. February 25, 2019 Ipsen Acquisition of Clementia Pharmaceuticals February 25, 2019 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements,

More information

Jefferies Healthcare Conference June 6, 2018

Jefferies Healthcare Conference June 6, 2018 Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development

More information

Investor Presentation

Investor Presentation Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities

More information

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell

More information

Tamsulosin Hydrochloride 0.4 mg Capsule

Tamsulosin Hydrochloride 0.4 mg Capsule Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule

More information

Cowen Healthcare Conference March 12, 2018

Cowen Healthcare Conference March 12, 2018 Cowen Healthcare Conference March 12, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development

More information

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

An exciting combination in a high growth, high margin Nutrition category. Name of chairman An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views

More information

For personal use only

For personal use only ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting

More information

MEDICAL CANNABIS COMPANY

MEDICAL CANNABIS COMPANY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - June 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward looking statements

More information

Investor Presentation December The vision to see past tomorrow

Investor Presentation December The vision to see past tomorrow Investor Presentation December 2011 The vision to see past tomorrow Safe Harbor Statement Certain statements contained herein are forward-looking statements (as such term is defined in the Private Securities

More information

AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018

AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning

More information

N A S D A Q : E V F M

N A S D A Q : E V F M N A S D A Q : E V F M Jefferies Global Healthcare Conference June 7, 2018 Disclaimer This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform

More information

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with

More information

Proprietary Pipeline

Proprietary Pipeline Revenue Generating Commercial portfolio with highquality, differentiated products in the Canadian market Proprietary Pipeline Reformulation development pipeline for drugs with a need for improved compliance

More information

Medimetriks Highlights

Medimetriks Highlights Medimetriks Highlights Specialty pharma company targeting medical Dermatology Established commercial operations with a Sales Force approaching 40 strong in key US markets Marketed brands for treatment

More information

Forward-Looking Statements

Forward-Looking Statements Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.

More information

SG Cowen 23rd Annual Health Care Conference March 18, Shire Pharmaceuticals Group plc

SG Cowen 23rd Annual Health Care Conference March 18, Shire Pharmaceuticals Group plc SG Cowen 23rd Annual Health Care Conference March 18, 2003 Shire Pharmaceuticals Group plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein

More information

Dainippon Sumitomo Pharma

Dainippon Sumitomo Pharma Progressing Towards an Internationally Competitive R&D-Oriented Pharmaceutical Company Dainippon Sumitomo Pharma Masayo Tada President and CEO 29th Annual J.P. Morgan Healthcare Conference January 11,

More information

Dynavax Corporate Presentation

Dynavax Corporate Presentation Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,

More information

Oragenics Shareholder Update

Oragenics Shareholder Update January 4, 2017 Oragenics Shareholder Update Advances Drug Development Programs Focused on Conditions with Significant Unmet Medical Needs TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE MKT:OGEN.BC),

More information

Investor Presentation

Investor Presentation ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an

More information

Positioned for Growth

Positioned for Growth Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation

More information

A Rare Opportunity in Transplant.

A Rare Opportunity in Transplant. A Rare Opportunity in Transplant. ENV-18-104.0 1 Forward Looking Statements Certain information in this presentation may constitute forward-looking information within the meaning of applicable securities

More information

Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference

Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's

More information

Committed to Transforming the Treatment Paradigm for Migraine Prevention

Committed to Transforming the Treatment Paradigm for Migraine Prevention Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying

More information

TSX Venture: RVV OTCQB: RVVTF

TSX Venture: RVV OTCQB: RVVTF TSX Venture: RVV OTCQB: RVVTF Corporate Presentation June 2018 Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com FORWARD LOOKING STATEMENTS Certain statements contained in this

More information

JP Morgan Healthcare Conference

JP Morgan Healthcare Conference JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and

More information

Titan Pharmaceuticals Overview

Titan Pharmaceuticals Overview Corporate Presentation July 2014 1 Safe Harbor The presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities

More information

Revolutionizing how advanced heart disease is treated. Alexei Marko, CEO Chris Clark, CFO November 2014

Revolutionizing how advanced heart disease is treated. Alexei Marko, CEO Chris Clark, CFO November 2014 Revolutionizing how advanced heart disease is treated Alexei Marko, CEO Chris Clark, CFO November 2014 Forward-Looking Statements Statements contained herein that are not based on historical or current

More information

BioMarin Pharmaceutical Inc. Conference Call to Discuss Approval of

BioMarin Pharmaceutical Inc. Conference Call to Discuss Approval of BioMarin Pharmaceutical Inc. Conference Call to Discuss Approval of For adult patients with PKU who have uncontrolled blood phenylalanine (Phe) concentrations > 600 µmol/l on existing management May 24,

More information

Revolutionizing how advanced heart disease is treated

Revolutionizing how advanced heart disease is treated LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained

More information

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission

More information

NASDAQ: GWPH March, 2019

NASDAQ: GWPH March, 2019 NASDAQ: GWPH March, 2019 Grace Living with Dravet syndrome, Being treated with Epidiolex 2019 GW Pharmaceuticals. All rights reserved. Forward-Looking Statements This presentation contains forward-looking

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

OWC PHARMACEUTICAL RESEARCH OTCQB:OWCP

OWC PHARMACEUTICAL RESEARCH OTCQB:OWCP OWC PHARMACEUTICAL RESEARCH OTCQB:OWCP Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively,

More information

SPECIALTY MEDICAL CANNABIS COMPANY

SPECIALTY MEDICAL CANNABIS COMPANY SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

Annual Shareholders Meeting

Annual Shareholders Meeting Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking

More information

Corporate Presentation

Corporate Presentation Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking

More information

More cancer patients are being treated with immunotherapy, but

More cancer patients are being treated with immunotherapy, but Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH

More information

Supernus Pharmaceuticals

Supernus Pharmaceuticals Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking

More information

Corporate Presentation Asia Investment Series March 2018

Corporate Presentation Asia Investment Series March 2018 Corporate Presentation Asia Investment Series March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United

More information

Aradigm Corporation. A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008

Aradigm Corporation. A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008 Aradigm Corporation A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008 Safe Harbor Statement This presentation contains forward-looking statements

More information

Idenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston

Idenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements

More information

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about

More information

Diagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015

Diagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015 Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking

More information

About X-Linked Hypophosphatemia (XLH)

About X-Linked Hypophosphatemia (XLH) Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal

More information

Corporate Overview NASDAQ: CLRB

Corporate Overview NASDAQ: CLRB Corporate Overview NASDAQ: CLRB Safe Harbor Statement 2 This presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this

More information

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or

More information

SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018

SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical

More information

Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting

Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment

More information

Paradigm for Migraine Patients

Paradigm for Migraine Patients June Transforming 14, 2018 the Prevention Treatment Paradigm for Migraine Patients January 2019 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking

More information

Innovation In Ophthalmology

Innovation In Ophthalmology Innovation In Ophthalmology INVELTYS TM Approval August 2018 Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform

More information

Avenue Therapeutics, Inc. September 2016

Avenue Therapeutics, Inc. September 2016 Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the

More information

OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP

OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively,

More information